Evidence map›Paper›PMID 41847707›Full record

ArticleFrontiers in oncology2026

The protease inhibitor gabexate mesylate targets Raf kinase inhibitor protein and reverses epithelial-mesenchymal transition in triple-negative breast cancer cells.

Marzia Deserti, Simone Sabbioni, Francesca Poli, Francesco Vasuri, Valeria Relli, Andrea Palloni, Chiara Deiana, Giovanni Brandi, Simona Tavolari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marzia DesertiDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Simone SabbioniDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Francesca PoliPathology Unit, Azienda Unità Sanitaria Locale (AUSL) of Imola, Imola, Italy.
Francesco VasuriDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Valeria RelliMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrea PalloniMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Chiara DeianaDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Giovanni BrandiMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Simona TavolariMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of triple-negative breast cancer (TNBC) still remains poor, mainly due to the occurrence of early metastases and the lack of effective treatments. The Raf kinase inhibitor protein (RKIP) is a tumor metastasis suppressor frequently downregulated in human cancers. Here, we report that RKIP expression is lost in the tumor tissue of TNBC patients. Treatment with the protease inhibitor gabexate mesylate (GM) increased RKIP expression and reverted the epithelial-mesenchymal transition (EMT) phenotype in MDA-MB-231 cells, a well-established

Indexed as

EMTgabexate mesylateRKIPTNBCtumor invasion

Identifiers

PMID41847707
PMCPMC12989336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.